Search Results
Your search for Karen Kelly, MD matches 14 pages
Showing 1 - 14Karen L. Kelly, MD, Named Chief Executive Officer of the International Association for the Study of Lung Cancer
The Board of Directors of the International Association for the Study of Lung Cancer (IASLC) is pleased to announce the appointment of Karen L. Kelly, MD to the position of Chief Executive Officer (CEO), effective Spring 2022. Dr. Kelly, a renowned medical oncologist, is an active, long-standing...
New Recommendations Offer Guidance for Clinicians and Patients on Genetic Testing for Prostate Cancer
An international panel of experts led by researchers and thought leaders at the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) and the Department of Urology at Jefferson have published the first multidisciplinary, consensus-driven, prostate cancer genetic implementation framework for the...
ASCO, Conquer Cancer Congratulate 2019 Grant and Award Recipients
Conquer Cancer®, the ASCO Foundation, presented more than $7 million in grants and awards to exceptional oncology researchers at the 2019 ASCO Annual Meeting. ASCO and Conquer Cancer congratulate the recipients and offer their profound thanks to those who generously supported these awards. Visit...
PACIFIC Trial of Durvalumab Sets Standard in Stage III Unresectable NSCLC
IMMUNOTHERAPY HAS revolutionized the treatment of lung cancer over the past several years. Although lung cancer is associated with immunosuppression at baseline for most patients, the addition of immune checkpoint inhibitors can overcome that suppression and lead to antitumor immune responses....
Durvalumab Takes a Giant Leap Into Stage III NSCLC
Immune checkpoint inhibitors have had a dramatic impact on survival for patients with stage IV non–small cell lung cancer (NSCLC), with whispers that a cure might be achieved in a subset of patients. In typical fashion, active new agents are evaluated in earlier stages of disease. Stage III NSCLC...
Experts Consider the New Immunotherapy Paradigm in Advanced Lung Cancer
One immune checkpoint inhibitor has now moved to the front of the line for treating advanced non–small cell lung cancer (NSCLC). Based on pivotal studies presented at the 2016 European Society for Medical Oncology (ESMO) Congress, pembrolizumab (Keytruda) became a first-line option, and it is...
Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC
For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently, the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) demonstrated superior survival ...
Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or...
Fellows of the American Society of Clinical Oncology: 2012 Recipients Will be Honored at ASCO Annual Meeting
Formerly called the ASCO Statesman Award, which launched in 2007, the new distinction of Fellow of the American Society of Clinical Oncology (FASCO) is designed to honor ASCO’s most active volunteer members. “The FASCO status represents recognition for the most dedicated volunteer members inside...
Pieces of the Puzzle in Treating Early Non–Small Cell Lung Cancer
Separate studies in early-stage non–small cell lung cancer (NSCLC) found that the addition of consolidation chemotherapy to concurrent chemoradiotherapy did not improve survival and that adjuvant erlotinib (Tarceva) did not improve survival. There was a suggestion of benefit for adjuvant erlotinib...
Revisiting Successes in Advanced NSCLC to Test Value in Earlier-Stage Disease
Some pretty good evidence suggests that chemotherapy that works in advanced disease probably works even better in early-stage disease,” said Fadlo R. Khuri, MD, Chair, Department of Hematology and Medical Oncology at Winship Cancer Institute in Atlanta, in summarizing results from trials of...
2015 ASCO Annual Meeting Planning Committees
The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with more than 28,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees, and thank them for their time and ...
Study Finds No Disease-Free Survival Improvement With Adjuvant Erlotinib in EGFR-Expressing NSCLC
In the phase III RADIANT trial reported in the Journal of Clinical Oncology, Kelly et al found no disease-free survival improvement with adjuvant erlotinib (Tarceva) vs placebo in patients with EGFR-expressing stage IB to IIIA non–small cell lung cancer (NSCLC). However, there was evidence of ...
Cancer in Young Adults Is Focus of New Nationwide Study to Be Led by Fred Hutchinson Cancer Research Center Survivorship Program
The Fred Hutchinson Cancer Research Center Survivorship Program and its directors, K. Scott Baker, MD, and Karen Syrjala, PhD, have been selected to lead a nationwide study that aims to improve long-term health outcomes for cancer survivors between the ages of 18 and 39. Underway this spring, the...
